Using a 5-20% (linear gradient) polyacrylamide slab gel electrophoresis, we studied the urinary protein collected from a 14-year-old girl with osteosarcoma during high-dose methotrexate (MTX) and leucovorin rescue therapy. A distinct protein band of approximately 30 kDa (P-30 protein) was observed in addition to albumin. We have never before encountered a 30 kDa urinary protein. Therefore, we first studied the P-30 protein by peptide mass fingerprinting and matrix-assisted laser desorption ionization-time of flight mass spectrometry (MALDI-TOF MS). We obtained the amino acid sequence "YDPSLKPLS-VSYDQATSLR", which is the same as that of amino acids (40-58) of human carbonic anhydrase II (CAII). Then, we confirmed this protein by Western blotting using anti-human CAII antibody. This enzyme distributes widely in the human bodies, in erythrocytes, kidney, and pancreas. We considered that this CAII originated from the kidney in association with high-dose MTX and leucovorin rescue therapy.
INTRODUCTION
High-dose MTX and leucovorin (calcium formyltetrahydropteroylglutamic acid) rescue therapy have been used to treat children with osteosarcoma [1] [2] [3] . MTX, a folic acid antagonist, deprives rapidly dividing cells of essential materials (reduced folates) at cell division. It inhibits not only the division of cancerous cells, but also that of normal cells such as bone marrow and intestinal epithelium. Leucovorin is infused to minimize such side effects 4) . The Department of Orthopedics of Niigata Cancer Center Hospital has conducted this therapy since December 1977. In our earlier study (n=4), the blood MTX level was 5.6×10 -7 -1.5×10 -6 M, 5.0×10 -8 -1.5×10 -7 M and 1× 10 -8 -1.5×10 -7 M, at 24 h, 48 h and 72 h after a 5-h MTX (100 mg/kg body weight) infusion, respectively 5) . These levels of blood MTX were within safe intervals 6) , i.e., lower than 1×10
-5 M, 1×10 -6 M and 1×10 -7 M, at 24 h, 48 h and 72 h after start of the infusion, respectively 6) . We also studied 1) liver function tests (serum AST, ALT, LDH, ALP and total bilirubin) and 2) renal function tests (serum Na, K, Cl, creatinine and BUN). However, no difference was seen in the data before and during this therapy 5) . In these cases, no side effects were seen except for slight mucositis.
Peyriere reported that during high-dose MTX therapy for a 14-year-old boy with osteosarcoma, severe intoxication was observed together with high MTX plasma concentration, acute renal failure, and hepatitis, followed by mucositis and moderate myelosuppression. Intensification of urine alkalinization and increased leucovorin dosages did not decrease plasma MTX nor prevent systemic toxicities 7) . Therefore, carboxyeptidase G2 and aminophylline were administered as a second-intention rescue strategy, and within 2 weeks the intoxication was overcome 7) . Optimal management of MTX intoxication is important for children with osteosarcoma.
The presence of CAI and CAII in human plasma has been known, and their excretions into the urine are higher in patients with kidney disease than apparently healthy subjects 8) . This, taken together with the two reports above, motivated us to study urinary proteins before and during high-dose MTX and leucovorin rescue therapy.
MATERIALS AND METHODS

Patient
Case: A 14-year-old girl suffering from osteosarcoma of the left thigh bone. No metastasis was detected, and no abnormal findings were observed in studies of urine and blood except for serum ALP. High-dose MTX (200 mg/kg) and leucovorin rescue therapy 5-h infusions were carried out as previously with only a slight modification 5) . Plasma, serum and urine were collected as shown in Table 2 .
Biochemical data of serum samples
Serum samples were collected at the time described in Table 1 for biochemical data. The following items were analyzed by a Hitachi 7600-110 automatic analyzer using the corresponding commercial kits: 1) total protein (TP), IatroFine TP (Biuret; Mitsubishi Kagaku Iatron, Inc., Tokyo, Japan), 2) aspartate transaminase (AST), CICA liquid AST (Kanto Chemical Co., Inc., Tokyo, Japan), 3) alanine transaminase (ALT), CICA liquid ALT (Kanto Chemical Co., Inc., Tokyo, Japan), 4) lactate dehydrogenase (LDH), CICA liquid LDH (Kanto Chemical Co., Inc., Tokyo, Japan), 5) alkaline phosphatase (ALP), CICA liquid ALP (Kanto Chemical Co., Inc., Tokyo, Japan), and 6) γ-glutamyltransferase (γ-GTP), CICA liquid γ-GTP (Kanto Chemical Co., Inc., Tokyo, Japan). These five enzyme assay kits were prepared according to the recommendations of the Japanese Society of Clinical Chemistry (JSCC), 7) choline esterase (Ch-E), a kit using DTNB of International Reagents Corporation (Kobe, Japan), 8) total bilirubin (T-Bil), Iatro LQ TBil (Mitsubishi Kagaku Iatron, Inc., Tokyo, Japan), 9) direct bilirubin (D-Bil), Iatro LQ D-Bil (Mitsubishi Kagaku Iatron, Inc., Tokyo, Japan), 10) total cholesterol (TC), a kit using cholesterol esterase and cholesterol dehydrogenase of International Reagents Corporation (Kobe, Japan), 11) blood urea nitrogen (BUN), N-assay BUN-L (UV assay, Nitto Boseki Co., Ltd., Japan), 12) creatinine (CRE), Nassay CRE-L (enzymatic method, Nitto Boseki Co., Ltd., Japan), and 13) electrolytes (Na, K and Cl), (ion-selective electrodes, reagents of Sysmex Corporation, Japan).
Measurement of MTX concentration of plasma or urine
MTX concentration in plasma or urine was measured using a commercial kit (METHOTREXATE II·Dinapack, Abbott Japan Co., Ltd.) and TDX analyzer (Abbott Japan Co., Ltd.) according to the manufacturer's instructions.
Measurement of urinary protein level
Concentration of urinary protein was measured as previously 9) . The sensitivity limit of this method is higher than or equal to 1 mg/dl 10) . 
SDS-PAGE
A 5-20% (linear gradient) polyacrylamide slab gel was used to study urinary protein 11) . A low molecular weight Calibration Kit for SDS Electrophoresis (Amersham Pharmacia Biotech UK Limited, UK) was used for molecular size markers. This kit contains phosphorylase b (rabbit muscle, 97 kDa), albumin (bovine serum, 66 kDa), ovalbumin (chicken egg, 45 kDa), carbonic anhydrase (bovine erythrocyte, 30 kDa), trypsin inhibitor (soybean, 20.1 kDa) and α-lactalbumin (bovine milk, 14.4 kDa).
Protein identification
Protein identification was carried out by peptide mass fingerprinting and matrix-assisted laser desorption ionization-time of flight mass spectrometry (MALDI-TOF MS) 12) at APRO Life Science Institute Inc., (URL, http://www. aprosci.com).
Western blotting
Western blotting was carried out as previously using anti human carbonic anhydrase II antibody (Rockland, Ltd., U.S.A.) 11) . PVDF membrane was purchased from BIO-RAD Laboratories, Tokyo, Japan.
RESULTS
Biochemical data
Biochemical data were summarized in Table 1 . On the 2nd day, AST and ALT increased to several times the level before infusion, then decreased slowly. LDH and ALP increased slightly from the 2nd to the 4th day. ALP was higher than normal interval due to osteosarcoma. T-Bil increased intermittently on the 1st and 2nd day. Only a small change was seen in γ-GTP and Ch-E. BUN, and creatinine and electrolytes did not change to indicate renal disturbance.
Concentration of urinary protein
The concentration of urinary protein was summarized in Table 2 . The peak was seen at 15 p.m. of the 1st day (24 mg/dl), then gradually decreased. 0 mg/dl was less than 1 mg/dl (sensitivity limit of this method).
MTX concentration in plasma or urine
At 10 a.m. of the 1st day, a 5-h MTX infusion was started. Plasma MTX levels were also summarized in Table 2 . Plasma MTX concentration was 4.6×10 Table 2 ). Almost of the MTX administered was excreted during the 1st and 2nd day.
SDS-PAGE patterns
SDS-PAGE patterns of urinary proteins were shown in 
Protein identification
The peptide fragment of the P-30 protein was analyzed by matrix-assisted laser desorption ionization-time of flight mass spectrometry (MALDI-TOF MS) and yielded the same amino acid sequence "YDPSLKPLSVSYDQATSLR" as the amino acid sequence 40-58 of CAII.
Western blotting
After a 5-20% (linear gradient) SDS-PAGE, Western blotting was carried out. The P-30 protein was confirmed to be CAII by this method using anti-human CAII antibody.
DISCUSSION
During high-dose MTX and leucovorin rescue therapy for patients with osteosarcoma, alkalinization (pH of urine>7) and hydration are important to prevent side effects of this therapy, such as renal failure, hepatitis and bone marrow suppression 7) . In our case, slight liver injury was seen because of the increase in serum AST, ALP and LDH. The serum ALP level, associated with osteosarcoma, was elevated before this therapy. Renal failure was not observed. The blood MTX concentration was lower than 1×10 -5 M, 1×10 -6 M and 1×10 -7 M, at 24 h, 48 h and 72 h after start of the infusion, respectively. These concentrations are at safe levels 6) . Maintaining alkalinization and hydration during this therapy, we suspected that changes in both the quality and quantity of urinary protein had occurred. Thereafter, we studied urinary protein before and during this therapy by SDS-PAGE. P-30 protein and albumin were observed as the main protein bands. We had never encountered urinary protein of 30 kDa. Then, we studied this P-30 protein by MALDI-TOF MS and Western blotting, and identified it as CAII.
CA catalyses the reversible hydration of carbon dioxide to bicarbonate. There are three CA families (α-, β-and γ-). CAII belongs to the α-CA family.
CAII belongs to the α-CA family. It is a cytoplasmic enzyme distributed in the proximal tubule, loop of Henle, and intercalated cells on the collecting duct of the kidney. CAII is reportedly excreted into the urine of patients with hypercalciuria or renal acidosis 13, 14) . In the present study, albumin and CAII were most prom- Albumin and P-30 protein are prominent in the urine of No. 5 and 7. P-30 protein is seen all the samples except for No. 0 and 1. Time of sample collection described in Table 2 . Fig. 2 . Profile of Western blotting of P-30 protein.
Lane 1, molecular size marker proteins; Lane 2, P-30 protein was visualized by Western blotting using anti-human carbonic anhydrase II antibody.
inent in the urine (No. 5 and No. 7). The peak of blood MTX concentration is reached at these points in time during this therapy (4-6 h after infusion) 5) . In addition, kidney is the major excretion organ for MTX7 7, 15) . Hence, we thought that CAII originated from the kidney, considering its distribution in the kidney, though serum BUN and creatinine did not increase and direct findings were lacking.
